Browse News
Filter News
Found 438 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Gene Therapy Market Size Poised to Surge USD 52.40 Billion by 2033
4/18/2024
The global gene therapy market size was valued at USD 8.75 billion in 2023 and is poised to grow from USD 10.47 billion in 2024
-
Viral Vector and Plasmid DNA Manufacturing Market Size, CAGR, Share, Report 2024 to 2033
4/16/2024
According to Vision Research Reports, the global viral vector and plasmid DNA manufacturing market size was estimated at around USD 5.37 billion
-
U.S. Gene Therapy Market Size, Share & Growth Report, 2033
4/12/2024
According to Nova One Advisor, the U.S. gene therapy market size was valued at USD 3.19 billion in 2023
-
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
3/28/2024
REGENXBIO Inc. (Nasdaq: RGNX) today announced the publication of results from the Phase I/IIa trial evaluating the safety and tolerability of a single dose of subretinal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (wet AMD).
-
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
3/27/2024
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days on Wednesday, April 3, 2024.
-
Duvyzat, which will be sold in the U.S. by ITF Therapeutics, joins a growing market that includes recently approved gene therapy Elevidys and corticosteroid Agamree.
-
Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
3/12/2024
Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.
-
REGENXBIO to Participate in Upcoming March 2024 Investor Conferences
3/11/2024
REGENXBIO Inc. announced it will participate the following upcoming investor conferences.
-
The recently launched company shared two posters at the Muscular Dystrophy Association’s annual conference this week ahead of a March 21 PDUFA date.
-
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
3/7/2024
REGENXBIO Inc. announced the pricing of an underwritten upsized public offering of 4,565,260 shares of its common stock at the price of $23.00 per share and 1,521,740 pre-funded warrants at a price of $22.9999 per warrant, in each case before underwriting discounts and commissions.
-
Regenxbio Announces New Positive Initial Efficacy Data From Affinity Duchenne® Trial
3/5/2024
REGENXBIO Inc. reported additional interim safety and efficacy data in the Phase I/II AFFINITY DUCHENNE® trial of RGX-202 in patients with Duchenne muscular dystrophy ages 4 to11 years old, including RGX-202 microdystrophin expression from dose level 2 and video of trial clinic assessments demonstrating initial evidence of strength and functional improvement.
-
REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial
2/29/2024
REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a live webcast to discuss new interim clinical data from the Phase I/II AFFINITY DUCHENNE® trial of RGX-202 for the treatment of Duchenne muscular dystrophy.
-
REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
2/27/2024
REGENXBIO Inc. (Nasdaq: RGNX) today announced financial results for the fourth quarter and full year ended December 31, 2023, and recent operational highlights, including progress on the strategic pipeline prioritization and corporate restructuring intended to significantly reduce operating expenses and support meaningful value generation from the Company's strong pipeline of AAV Therapeutics.
-
REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
2/21/2024
REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, February 27, 2024, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2023, and recent operational highlights.
-
REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint
2/7/2024
REGENXBIO Inc. (Nasdaq: RGNX) today announced topline results from the Phase I/II/III CAMPSIITE® trial of RGX-121 for the treatment of patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II (MPS II) demonstrating that the pivotal phase of the trial met its primary endpoint with statistical significance.
-
REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial
2/7/2024
REGENXBIO Inc. (Nasdaq: RGNX) today announced that enrollment has completed at dose level 2 and reported additional interim safety and efficacy in the Phase I/II AFFINITY DUCHENNE® trial of RGX-202 in patients with Duchenne muscular dystrophy (Duchenne) ages 4 to11 years old.
-
REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024
1/31/2024
REGENXBIO Inc. announced presentations on its program for the treatment of mucopolysaccharidosis type II, also known as Hunter syndrome, will be shared at the 20th Annual WORLDSymposium™ 2024, taking place in San Diego, CA February 3-9, 2024.
-
REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
1/16/2024
REGENXBIO Inc. (Nasdaq: RGNX) today announced positive interim data from the Phase II AAVIATE® trial of ABBV-RGX-314 for the treatment of wet age-related macular degeneration (wet AMD) using suprachoroidal delivery. Wet AMD is a chronic, life-long disease with available anti-VEGF treatment options that may reduce the risk of blindness, but require frequent injections.
-
REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting
1/10/2024
REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present data from the Phase II AAVIATE ® trial of suprachoroidal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD) at Hawaiian Eye and Retina 2024 Meeting being held January 13-19, 2024 in Maui, HI.